<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1705222041
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Breztri Aerosphere
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FORMOTEROL FUMARATE,GLYCOPYRRONIUM BROMIDE,BUDESONIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5,7.2,160
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Pressurised inhalation, suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pressurised container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        236.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AstraZeneca Dunkerque Production (AZDP)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AstraZeneca Dunkerque Production (AZDP)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03AL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Breztri Aerosphere contains three active substances: formoterol fumarate dihydrate, glycopyrronium, and budesonide.</p><ul dir="ltr"><li>Formoterol fumarate dihydrate and glycopyrronium belong to a group of medicines called &lsquo;bronchodilators&rsquo;. They work in different ways to prevent tightening of the muscles around the airways, making it easier for air to get in and out of the lungs.</li><li>Budesonide belongs to a group of medicines called &lsquo;corticosteroids&rsquo;. These work by reducing inflammation in your lungs.</li></ul><p dir="ltr">&nbsp;</p><p dir="ltr">Breztri Aerosphere is an inhaler that is used for adults with a lung disease called &lsquo;chronic obstructive pulmonary disease&rsquo; (or &lsquo;COPD&rsquo;), a long-term disease of the airways in the lungs.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Breztri Aerosphere is used to make breathing easier and improve symptoms of COPD such as shortness of breath, wheezing and cough. Breztri Aerosphere can also prevent flare-ups (exacerbations) of COPD.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Breztri Aerosphere delivers the active substances into your lungs as you breathe in. If you use this medicine regularly twice a day, it will help to reduce the effects of COPD on your everyday life.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not use Breztri Aerosphere</strong></p><ul dir="ltr"><li>&nbsp;if you are allergic to formoterol fumarate dihydrate, glycopyrronium, budesonide or any of the other ingredients of this medicine (listed in section 6).</li></ul><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Warnings and precautions </strong></p><p dir="ltr">Breztri Aerosphere is used as a long-term maintenance treatment for COPD. <strong>Do not use it to treat a sudden attack of breathlessness or wheezing.</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Immediate breathing difficulties </strong></p><p dir="ltr">If you get tightness of the chest, coughing, wheezing or breathlessness immediately after using Breztri Aerosphere, <strong>stop using it and tell your doctor straight away</strong><strong> </strong>(see &lsquo;Serious side effects&rsquo; at the top of Section 4 for more information).<strong> &nbsp;</strong></p><p dir="ltr">If your breathlessness, tightness of the chest, wheezing or coughing is getting worse while using Breztri Aerosphere, you should continue to use Breztri Aerosphere but contact your doctor as soon as possible, as you may need additional treatment.</p><p dir="ltr"><strong>Talk to your doctor before using Breztri Aerosphere if:</strong></p><ul dir="ltr"><li>you have high blood pressure or heart problems</li><li>&nbsp;you have diabetes</li><li>you have a lung infection</li><li>&nbsp;you have problems with your thyroid gland</li><li>&nbsp;you have low levels of potassium in your blood</li><li>&nbsp;you have prostate problems or any problems passing urine</li><li>you have an eye problem called &lsquo;angle-closure glaucoma&rsquo;</li><li>&nbsp;you have kidney or liver problems.</li></ul><p dir="ltr">Talk to your doctor if you think any of these may apply to you.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Children and adolescents</strong></p><p dir="ltr">Breztri Aerosphere has not been studied in children and adolescents. Do not give this medicine to children or adolescents below the age of 18&nbsp;years.</p><p dir="ltr"><strong>Other medicines and Breztri Aerosphere</strong></p><p dir="ltr">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, and herbal medicines. This is because Breztri Aerosphere can affect the way some medicines work. Also some medicines can affect how Breztri Aerosphere works, or make it more likely that you will have side effects.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Tell your doctor or pharmacist if you are taking any of the following:</p><ul dir="ltr"><li>medicines called beta-blockers (such as atenolol or propranolol), that may be used for high blood pressure or heart problems, or to treat glaucoma (such as timolol)</li><li>medicines which are used to treat fungal infections &ndash; such as ketoconazole or itraconazole</li><li>medicines which are used to treat HIV infection &ndash; such as ritonavir or cobicistat</li><li>medicines that lower the amount of potassium in your blood, such as:</li></ul><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -&nbsp; &nbsp;corticosteroids that you take by mouth (such as prednisolone), diuretics &ndash; medicines that increase urine production (such as furosemide or hydrochlorothiazide), which can be used for treating high blood pressure,</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; some medicines used to treat breathing problems (such as theophylline) &ndash; called &lsquo;methylxanthines&rsquo;.</p><ul dir="ltr"><li>any medicines that work in the same way as Breztri Aerosphere &ndash; such as tiotropium, ipratropium, aclidinium, umeclidinium or salmeterol, arformoterol, vilanterol, olodaterol or indacaterol. Do not use Breztri Aerosphere if you already use these medicines.</li><li>medicines which are used to treat heart rhythm problems &ndash; such as amiodarone</li><li>medicines which can change some electrical activity of the heart (called the &lsquo;QT interval&rsquo;) &ndash; such as medicines for:</li></ul><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -&nbsp;&nbsp;depression (such as monoamine oxidase inhibitors or tricyclic antidepressants),</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -&nbsp;&nbsp;bacterial infections (such as erythromycin, clarithromycin or telithromycin),</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -&nbsp; &nbsp;allergic reactions (anti-histamines).</p><p dir="ltr">If any of the above applies to you, or if you are not sure, talk to your doctor or pharmacist before using Breztri Aerosphere.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pregnancy and breast-feeding </strong></p><p dir="ltr">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p dir="ltr">Do not use Breztri Aerosphere if you are pregnant unless your doctor tells you that you can.</p><p dir="ltr">Do not use this medicine if you are breast-feeding unless your doctor tells you that you can.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr">It is unlikely that this medicine will affect your ability to drive or use machines. However, dizziness is an uncommon side effect which should be taken into account when driving or using machines.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr"><strong>How much to use</strong></p><p dir="ltr">The recommended dose is two puffs twice a day &ndash; two puffs in the morning and two puffs in the evening.</p><p dir="ltr">It is important to use Breztri Aerosphere every day &ndash; even if you have no COPD symptoms at the time.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Remember</strong>: Always rinse your mouth with water after using Breztri Aerosphere. This is to remove any medicine which is left in the mouth. Spit this water out &ndash; do not swallow.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>How to use</strong></p><p dir="ltr">Breztri Aerosphere is for inhalation use.</p><p dir="ltr">Please read the &lsquo;Instructions for Use&rsquo; at the end of this leaflet. If you are not sure how to use Breztri Aerosphere, talk to your doctor or pharmacist.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Using Breztri Aerosphere with a spacer</strong></p><p dir="ltr">You may find it difficult breathing in and pressing the inhaler at the same time. If this happens, talk to your doctor or pharmacist. It may help to use a &lsquo;spacer&rsquo; with your inhaler.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you use more Breztri Aerosphere than you should</strong></p><p dir="ltr">If you have used more Breztri Aerosphere than you should, talk to a doctor or pharmacist straight away. You may need medical attention. You may notice that your heart is beating faster than usual, you feel shaky, you have problems with your sight, you have a dry mouth or you have a headache or feel sick (nausea).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you forget to use Breztri Aerosphere</strong></p><p dir="ltr">Do not take a double dose to make up for a forgotten dose. Take it as soon as you remember.</p><p dir="ltr">However, if it is nearly time for your next dose, skip the missed dose. Do not take more than two puffs twice a day on the same day.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you stop using Breztri Aerosphere</strong></p><p dir="ltr">This medicine is for long-term use. Use this medicine for as long as your doctor tells you to. It will only be effective as long as you are using it.</p><p dir="ltr">Do not stop unless your doctor tells you to &ndash; even if you feel better &ndash; as your symptoms may get worse. If you want to stop treatment, talk to your doctor first.</p><p dir="ltr">If you have any further questions on the use of this medicine, talk to your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p><strong>Serious side effects</strong></p><p><strong>Uncommon</strong> (may affect up to 1 in 100&nbsp;people)</p><p><strong>Immediate breathing difficulties</strong>:</p><ul><li>if you get breathing difficulties straight after using Breztri Aerosphere, such as tightness of the chest, coughing, wheezing or feeling breathless, <strong>stop using this medicine</strong> and <strong>tell your doctor straight away</strong>.</li></ul><p><strong>Allergic reactions</strong>:</p><ul><li>swelling of your face, particularly around your mouth (swelling of your tongue or throat may make it difficult to swallow)</li><li>rash or hives together with difficulty breathing</li><li>suddenly feeling faint</li></ul><p>These symptoms may be signs of an allergic reaction which may become serious. Stop using this medicine and call for medical help straight away if you notice the serious side effects above.&nbsp; &nbsp;</p><p><strong>Other side effects</strong></p><p>Tell your doctor or pharmacist if you notice any of the following side effects:</p><p><strong>Common</strong> (may affect up to 1 in 10&nbsp;people)</p><ul><li>thrush in the mouth (a fungal infection). Rinsing your mouth out with water immediately after using Breztri Aerosphere may help prevent this.</li><li>feeling anxious</li><li>difficulty sleeping</li><li>feeling sick (nausea)</li><li>&nbsp;headache</li><li>coughing or a hoarse voice</li><li>muscle cramps</li><li>awareness of your heart beating (palpitations)</li><li>&nbsp;high blood sugar levels (as shown in tests)</li><li>&nbsp;painful and frequent urination (may be signs of a urinary tract infection)</li><li>pneumonia (infection of the lung).</li></ul><p>Tell your doctor if you have any of the following while using Breztri Aerosphere, they could be symptoms of a lung infection:</p><ul><li>fever or chills,</li><li>&nbsp;increased mucus production, change in mucus colour,</li><li>increased cough or increased breathing difficulties.</li></ul><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><ul><li>shaking, tremor or feeling dizzy</li><li>dry mouth, or mild irritation in the throat</li><li>bruising of the skin</li><li>feeling restless, nervous or agitated</li><li><p>depression</p></li><li><p>fast heart beat or uneven heart beat</p></li><li><p>chest pain or tightening in the chest (angina pectoris)</p></li></ul><p><strong>Very rare</strong> (may affect up to 1 in 10,000&nbsp;people)</p><ul><li>changes in behaviour</li><li>an effect on the adrenal gland</li></ul><p><strong>Not known</strong> (frequency cannot be estimated from the available data):</p><ul><li>&nbsp;blurred vision</li><li>&nbsp;clouding of the lens of your eyes (signs of cataract)</li><li>&nbsp;increased pressure in the eye (glaucoma)</li><li>&nbsp;swelling of your face, particularly around your mouth (swelling of your tongue or throat may make it difficult to swallow)</li></ul><p>&nbsp;</p><p>To report any side effect(s):</p><ul><li><strong><em>Saudi Arabia: </em></strong></li></ul><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>- </strong>The National Pharmacovigilance Centre (NPC)</p><ul><li>Fax: +966-11-205-7662</li><li>Toll free phone: 19999</li><li>E-mail: npc.drug@sfda.gov.sa&nbsp;&nbsp;</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><ul><li>Other GCC States:</li></ul><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight and reach of children.</p><p dir="ltr">Do not use Breztri Aerosphere after the expiry date which is stated on the carton, pouch and pressurised container after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p dir="ltr">After opening the pouch, the inhaler must be used within:</p><ul dir="ltr"><li>3 months</li></ul><p dir="ltr">Keep the inhaler inside the sealed pouch &ndash; only remove the inhaler from the sealed pouch immediately before first use. On the day the pouch is opened, write the date on the inhaler label in the space provided.</p><p dir="ltr">Do not store above 30<sup>o</sup>C. Store in a dry place. <sup>&nbsp;&nbsp;</sup></p><p dir="ltr">For best results, the inhaler should be at room temperature before you use it.<strong>&nbsp;</strong></p><p dir="ltr">Do not break, puncture or burn the pressurised container, even when apparently empty. Do not use or store near heat or open flames.</p><p dir="ltr">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substances are formoterol fumarate dihydrate, glycopyrronium and budesonide.</p><p dir="ltr">Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 5&nbsp;micrograms of formoterol fumarate dihydrate, 9&nbsp;micrograms glycopyrronium bromide equivalent to 7.2&nbsp;micrograms glycopyrronium and 160&nbsp;micrograms of budesonide.</p><p dir="ltr">The other ingredients are norflurane, 1,2- distearoyl-sn-glycero-3-phosphocholine and calcium chloride.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Breztri Aerosphere is a pressurised inhalation, suspension.

 The mouthpiece is covered with a removable grey protective cap. Breztri Aerosphere is supplied in a foil pouch that contains a drying packing (desiccant) and packed into a carton.
	
Each inhaler contains 120 puffs. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Marketing Authorisation Holder </strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">AstraZeneca AB</p><p dir="ltr">SE-151 85 S&ouml;dert&auml;lje</p><p dir="ltr">Sweden</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Manufacturer</strong></p><p dir="ltr">AstraZeneca Dunkerque Production</p><p dir="ltr">224 Avenue de la Dordogne</p><p dir="ltr">Dunkerque</p><p dir="ltr">59640</p><p dir="ltr">France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي بريزتري إيروسفير على ثلاث مواد فعالة: فورموتيرول فومارات ثنائي الهيدرات، وغليكوبيرونيوم، وبيوديزونايد.</p><ul><li dir="RTL">ينتمي كل من فورموتيرول فومارات ثنائي الهيدرات، وغليكوبيرونيوم إلى مجموعة من الأدوية تسمى &quot;موسعات الشُعب الهوائية&quot;. فهي تعمل بطرق مختلفة لمنع شد العضلات حول المسالك الهوائية، مما يسهل دخول الهواء إلى الرئتين وخروجه منهما.</li><li dir="RTL">ينتمي بيوديزونايد إلى مجموعة من الأدوية يُطلق عليها &quot;الكورتيكوستيرويدات&quot;. وتعمل هذه الأدوية على تقليل الالتهاب في الرئتين.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">بريزتري إيروسفير عبارة عن جهاز استنشاق يُستخدم للبالغين الذين يعانون من مرض رئوي يُسمى &quot;مرض الانسداد الرئوي المزمن&quot; (أو &quot;COPD&quot;)، وهو مرض طويل الأمد يُصيب المسالك الهوائية في الرئتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم بريزتري إيروسفير لتسهيل التنفس وتخفيف أعراض مرض الانسداد الرئوي المزمن مثل ضيق التنفس والأزيز والسعال. كما يمكن لبريزتري إيروسفير أيضًا أن يمنع نوبات الاحتدام (التفاقمات) لمرض الانسداد الرئوي المزمن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يقوم بريزتري إيروسفير بتوصيل المواد الفعالة إلى رئتيك أثناء الشهيق. إذا كنت تستخدم هذا الدواء بانتظام مرتين يوميًا، فسيساعد ذلك في تقليل آثار مرض الانسداد الرئوي المزمن على حياتك اليومية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم بريزتري إيروسفير</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه فورموتيرول فومارات ثنائي الهيدرات أو غليكوبيرونيوم أو بيوديزونايد أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p>يُستعمَل بريزتري إيروسفير كعلاج مداومة طويل الأمد لداء الانسداد الرئوي المزمن. <strong>لا تستخدمه لعلاج نوبة مفاجئة من ضيق التنفس أو الأزيز.</strong></p><p dir="RTL"><strong>صعوبات مباشرة في التنفس </strong></p><p dir="RTL">إذا أصبت بضيق في الصدر أو سعال أو أزيز أو ضيق في التنفس مباشرة بعد استخدام بريزتري إيروسفير، <strong>فتوقف عن استخدامه وأخبر طبيبك على الفور </strong>(انظر &quot;الآثار الجانبية الخطيرة&quot; في أعلى القسم 4 لمزيد من المعلومات).<strong> </strong></p><p dir="RTL">إذا كان ضيق التنفس أو ضيق الصدر أو الأزيز أو السعال لديك يزداد سوءًا أثناء استخدام بريزتري إيروسفير، فيجب عليك الاستمرار في استخدام بريزتري إيروسفير ولكن اتصل بطبيبك في أقرب وقت ممكن، حيث قد تحتاج إلى علاج إضافي.</p><p dir="RTL"><strong>تحدث إلى طبيبك قبل استخدام بريزتري إيروسفير إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من ارتفاع ضغط الدم أو مشكلات في القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بمرض السكري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بعدوى رئوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات في الغدد الدرقية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مستويات منخفضة من البوتاسيوم في دمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشاكل في البروستاتا أو أي مشاكل في التبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشكلة في العين تسمى &quot;زرق انسداد الزاوية&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك مشكلات في الكلى أو الكبد.</p><p dir="RTL">تحدث إلى طبيبك إذا كنت تعتقد أن أيًا من هذه قد ينطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لم تتم دراسة بريزتري إيروسفير على الأطفال والمراهقين. لا تعطِ هذا الدواء للأطفال أو المراهقين ممن يقل عمرهم عن 18&nbsp;عامًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وبريزتري إيروسفير</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو إذا تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى. ويشمل هذا الأدوية التي قد تشتريها دون وصفة طبية والأدوية العشبية. وذلك لأن بريزتري إيروسفير يمكن أن يؤثر على طريقة عمل بعض الأدوية. كما يمكن أن تؤثر بعض الأدوية على كيفية عمل بريزتري إيروسفير، أو تزيد من احتمالية تعرضك لآثار جانبية.</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أي مما يلي:</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;الأدوية التي يُطلق عليها اسم حاصرات بيتا (مثل أتينولول أو بروبرانولول)، والتي يمكن استخدامها لعلاج ارتفاع ضغط الدم أو مشكلات القلب أو لعلاج الجلوكوما (مثل تيمولول)</li><li>&nbsp; &nbsp; &nbsp;الأدوية التي تُستخدم لعلاج الالتهابات الفطرية - مثل كيتوكونازول أو إيتراكونازول</li><li>&nbsp; &nbsp; &nbsp;الأدوية التي تُستخدم لعلاج عدوى فيروس نقص المناعة البشرية - مثل ريتونافير أو كوبيسيستات</li><li>&nbsp; &nbsp; &nbsp;الأدوية التي تخفض كمية البوتاسيوم في الدم، مثل:</li></ul><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- الكورتيكوستيرويدات التي تتناولها عن طريق الفم (مثل بريدنيزولون)،</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - مدرات البول - الأدوية التي تزيد من عملية التبول (مثل فوروسيميد أو هيدروكلوروثيازيد)، والتي يمكن استخدامها لعلاج ارتفاع ضغط الدم،</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; بعض الأدوية التي تُستخدم لعلاج مشاكل التنفس (مثل ثيوفيلين) - تُسمى &quot;ميثيل زانثين&quot;،</p><ul dir="rtl"><li>&nbsp; &nbsp; أي أدوية تعمل بنفس الطريقة التي يعمل بها دواء بريزتري إيروسفير - مثل تيوتروبيوم أو إبراتروبيوم أو اكليدينيوم أو أوميكليدينيوم أو سالميترول أو أرفورموتيرول أو فيلانتيرول أو أولوداتيرول أو إنداكاتيرول. لا تستخدم بريزتري إيروسفير إذا كنت تستخدم هذه الأدوية بالفعل.</li><li>&nbsp; &nbsp; أدوية تُستخدم لعلاج مشاكل ضربات القلب - مثل أميودارون</li><li>&nbsp; &nbsp; الأدوية التي يمكن أن تغير بعض النشاط الكهربائي للقلب (تسمى &quot;فترة كيو تي&quot;) - مثل أدوية:</li></ul><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- الاكتئاب (مثل مثبطات أوكسيديز أحادي الأمين أو مضادات الاكتئاب ثلاثية الحلقات)،</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - الالتهابات البكتيرية (مثل إريثروميسين أو كلاريثروميسين أو تيليثرومايسين)،</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; ردود الفعل التحسسية (مضادات الهيستامين).</p><p dir="RTL">إذا كنت تتناول أيًا مما سبق، أو إذا لم تكن متأكدًا، فتحدث إلى طبيبك أو الصيدلي قبل استخدام بريزتري إيروسفير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين طبيعيًا، أو تعتقدين أنكِ حاملًا، أو تخططين لإنجاب طفل، فاطلبي المشورة من طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">لا تستخدمي بريزتري إيروسفير إذا كنتِ حاملًا إلا إذا أخبركِ طبيبكِ أنكِ تستطيعين ذلك.</p><p dir="RTL">لا تستخدمي هذا الدواء إذا كنتِ ترضعين رضاعة طبيعية إلا إذا أخبركِ طبيبكِ بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثر هذا الدواء على قدرتك على القيادة أو استخدام الآلات. ومع ذلك، يُعد الدوار أثر جانبي غير شائع يجب أخذه في الاعتبار عند القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدواء دائمًا بحسب توجيهات الطبيب تمامًا. استشر طبيبك أو الصيدلي إذا كانت تساورك أيّ شكوك.</p><p dir="RTL"><strong>عدد مرات الاستخدام</strong></p><p dir="RTL">الجرعة الموصى بها هي بختان بمعدل مرتين في اليوم - بختان في الصباح وبختان في المساء.</p><p dir="RTL">من المهم استخدام بريزتري إيروسفير كل يوم - حتى لو لم تظهر عليك أعراض مرض الانسداد الرئوي المزمن في ذلك الوقت.</p><p dir="RTL"><strong>تذكّر:</strong> اشطف فمك بالماء دائمًا بعد استخدام بريزتري إيروسفير. وذلك لإزالة أي دواء متبقي في الفم. ابصق هذا الماء - لا تبتلعه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية الاستخدام</strong></p><p dir="RTL">بريزتري إيروسفير مخصص للاستخدام عن طريق الاستنشاق.</p><p dir="RTL">يُرجى قراءة &quot;تعليمات الاستخدام&quot; في نهاية هذه النشرة. إذا لم تكن متأكدًا من كيفية استخدام بريزتري إيروسفير، فتحدث إلى طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام بريزتري إيروسفير مع مفساح</strong></p><p dir="RTL">قد تجد صعوبة في التنفس والضغط على جهاز الاستنشاق في نفس الوقت. إذا حدث ذلك، فتحدث إلى طبيبك أو الصيدلي. قد يكون من المفيد استخدام &quot;مفساح&quot; مع جهاز الاستنشاق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استعملت كمية زائدة من بريزتري إيروسفير أكثر مما ينبغي</strong></p><p dir="RTL">إذا استعملت كمية زائدة من بريزتري إيروسفير أكثر مما ينبغي، فتحدث إلى طبيب أو صيدلي على الفور. قد تحتاج إلى رعاية طبية. قد تلاحظ أن قلبك ينبض أسرع من المعتاد، أو تشعر بالارتعاش، أو تعاني من مشكلات في الرؤية، أو جفاف الفم، أو تعاني من صداع أو تشعر بالغثيان (القيء).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام بريزتري إيروسفير</strong></p><p dir="RTL">لا تأخذ جرعة مضاعفة لتعويض أيّ جرعة فائتة. استخدمه بمجرد أن تتذكر.</p><p dir="RTL">ولكن إذا اقترب وقت الجرعة التالية، فلا تتناول الجرعة الفائتة. لا تأخذ أكثر من بختين بمعدل مرتين في اليوم في نفس اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام بريزتري إيروسفير</strong></p><p dir="RTL">هذا الدواء مخصص للاستعمال طويل الأمد. استخدم هذا الدواء طالما أخبرك طبيبك بذلك. ولن يكون فعالًا إلا إذا كنت تستخدمه.</p><p dir="RTL">لا تتوقف إلا إذا أخبرك طبيبك بذلك - حتى لو شعرت بتحسن - لأن أعراضك قد تزداد سوءًا. إذا كنت ترغب في التوقف عن العلاج، فتحدث إلى طبيبك أولًا.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، فتحدث إلى طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب هذا الدواء، شأنه شأن جميع الأدوية، آثارًا جانبية، على الرغم من أنها لا تصيب الجميع. قد تحدث الآثار الجانبية التالية عند تناول هذا الدواء:</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p><strong>غير شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل 100&nbsp;شخص):</p><p dir="RTL"><strong>صعوبات مباشرة في التنفس:</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; إذا عانيت من صعوبات في التنفس مباشرة بعد استخدام بريزتري إيروسفير، مثل ضيق الصدر أو السعال أو الأزيز أو الشعور بضيق التنفس، <strong>فتوقف عن استخدام هذا الدواء</strong> و<strong>أخبر طبيبك على الفور.</strong></li></ul><p dir="RTL"><strong>ردود الفعل التحسسية:</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;تورم وجهك، خاصة حول الفم (تورم اللسان أو الحلق الذي قد يؤدي إلى الشعور بصعوبة في البلع)</li><li>&nbsp; &nbsp; &nbsp;طفح جلدي أو شرى مع صعوبة في التنفس</li><li>&nbsp; &nbsp; &nbsp;الشعور بالإغماء فجأة</li></ul><p dir="RTL">قد تكون هذه الأعراض علامات على رد فعل تحسسي قد يصبح خطيرًا. توقف عن استخدام هذا الدواء واطلب المساعدة الطبية على الفور إذا لاحظت الآثار الجانبية الخطيرة المذكورة أعلاه. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية أخرى</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا لاحظت أيًا من الآثار الجانبية التالية:</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب شخص واحد من بين كل 10&nbsp;أشخاص)</p><ul dir="rtl"><li>&nbsp; &nbsp; قلاع في الفم (عدوى فطرية). قد يساعد شطف فمك بالماء فورًا بعد استخدام بريزتري إيروسفير على منع ذلك.</li><li>&nbsp; الشعور بالقلق</li><li>&nbsp; صعوبة في النوم</li><li>&nbsp;الشعور بالإعياء (الغثيان)</li><li>&nbsp; الصداع</li><li>&nbsp; سعال أو بحة في الصوت</li><li>&nbsp;التشنجات العضلية</li><li>الوعي بنبض القلب (الخفقان)</li><li>&nbsp;ارتفاع مستويات السكر في الدم (كما هو موضح في الاختبارات)</li><li>التبول المؤلم والمتكرر (قد تكون هذه علامات على التهاب المسالك البولية)</li><li>&nbsp;الالتهاب الرئوي (عدوى الرئة)</li></ul><p dir="RTL">أخبر طبيبك إذا كنت تعاني من أي مما يلي أثناء استخدام بريزتري إيروسفير، فقد تكون أعراضًا لعدوى الرئة:</p><ul dir="rtl"><li>حمى أو قشعريرة،</li><li>زيادة إفراز المخاط أو تغير لونه،</li><li>زيادة في السُعال أو صعوبة التنفس.</li></ul><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل 100 شخص):</p><ul dir="rtl"><li>&nbsp;الرجفة، أو الارتعاش، أو الشعور بالدوار</li><li>جفاف الفم، أو تهيج خفيف في الحلق</li><li>كدمات في الجلد</li><li>الشعور بالقلق أو التوتر أو الغضب</li><li>&nbsp;الاكتئاب</li><li>&nbsp;سرعة ضربات القلب أو عدم انتظام ضربات القلب</li><li>&nbsp; ألم أو ضيق في الصدر (الذبحة الصدرية)</li></ul><p dir="RTL"><strong>نادرة جدًا</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل 10,000&nbsp;شخص)</p><ul dir="rtl"><li>&nbsp; &nbsp; تغيرات في السلوك</li><li>&nbsp; &nbsp; تأثير على الغدة الكظرية</li></ul><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقدير معدل الحدوث من البيانات المتاحة):</p><ul dir="rtl"><li>&nbsp;عدم وضوح الرؤية</li><li>إعتام عدسة عينيك (علامات إظلام عدسة العين)</li><li>زيادة الضغط في العين (الجلوكوما)</li><li>تورم وجهك، خاصة حول الفم (تورم اللسان أو الحلق الذي قد يؤدي إلى الشعور بصعوبة في البلع)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أي أثر (آثار) جانبية او اية مشكلات تتعلق بالجودة:</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكه العربيه السعوديه</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية:</strong></p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الرقم المجاني : </strong><strong>19999</strong></p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>البريد الإلكتروني: </strong><strong>npc.drug@sfda.gov.sa</strong></p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الموقع الإلكتروني: </strong><strong>https://ade.sfda.gov.sa/</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول مجلس التعاون الخليجي الاخرى</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>يرجى الاتصال بالجهة المختصة ذات الصله</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن متناول الأطفال وعن أعينهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم بريزتري إيروسفير بعد تاريخ انتهاء الصلاحية المدون على العلبة، والكيس، والحاوية المضغوطة بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في هذا الشهر.</p><p dir="RTL">بعد فتح الكيس، يجب استخدام جهاز الاستنشاق في غضون:</p><ul><li dir="RTL">3 أشهر&nbsp;</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بجهاز الاستنشاق داخل الكيس المغلق - قم فقط بإزالة جهاز الاستنشاق من الكيس المغلق قبل الاستخدام لأول مرة. في يوم فتح الكيس، اكتب التاريخ على ملصق جهاز الاستنشاق في المساحة المتوفرة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يُخزن في درجة حرارة أعلى من ٣٠ درجة مئوية. يُخزن في مكان جاف.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للحصول على أفضل النتائج، يجب أن يكون جهاز الاستنشاق في درجة حرارة الغرفة قبل استخدامه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تكسر الحاوية المضغوطة أو تثقبها أو تحرقها، حتى عندما يبدو عليها أنها فارغة. لا تستعمله أو تخزنه بالقرب من مصادر الحرارة أو ألسنة اللهب المكشوفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية في مياه الصرف الصحي أو مكب النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الذي يحتوي عليه بريزتري إيروسفير </strong></p><p dir="RTL">المواد الفعالة وهي فورموتيرول فومارات ثنائي الهيدرات، وغليكوبيرونيوم، وبيوديزونايد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توفر كل عملية استنشاق واحدة جرعة مُعطاة (الجرعة التي تغادر قطعة الفم) والتي تبلغ 5&nbsp;ميكروغرام من فورموتيرول فومارات ثنائي الهيدرات، و9&nbsp;ميكروغرام من غليكوبيرونيوم بروميد بما يعادل 7.2&nbsp;ميكروغرام من غليكوبيرونيوم و160&nbsp;ميكروغرام من بيوديزونايد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي نورفلوران، و1,2-ديسترويل-س.ن.-3-فوسفوكولين، وكلوريد الكالسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل بريزتري إيروسفير ومحتويات العبوة</strong></p><p dir="RTL">بريزتري إيروسفير عبارة عن مستنشق بالضغط، مستعلق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قطعة الفم مغطاة بغطاء واقٍ رمادي قابل للإزالة. يأتي بريزتري إيروسفير في غلاف من رقائق الألومنيوم يحتوي على عبوة تجفيف (مادة مجففة) ومُعبّأ في علبة كرتون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل جهاز استنشاق على 120&nbsp;بخّة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق </strong></p><p dir="RTL">AstraZeneca AB</p><p dir="RTL">SE-151 85 S&ouml;dert&auml;lje</p><p dir="RTL">السويد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التصنيع</strong></p><p dir="RTL">إنتاج شركة AstraZeneca Dunkerque</p><p dir="RTL">224 Avenue de la Dordogne</p><p dir="RTL">Dunkerque</p><p dir="RTL">59640</p><p dir="RTL">فرنسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Breztri Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each single actuation (delivered dose, ex-actuator) contains 5 micrograms of formoterol fumarate dihydrate, glycopyrronium bromide 9 micrograms, equivalent to 7.2 micrograms of glycopyrronium, and budesonide 160 micrograms.
This corresponds to a metered dose of 5.8 micrograms of formoterol fumarate dihydrate, glycopyrronium bromide 10.4 micrograms, equivalent to 8.2 micrograms of glycopyrronium, and budesonide 182 micrograms.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pressurised inhalation, suspension.

White suspension. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Breztri Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long‑acting beta2‑agonist or combination of a long-acting beta2‑agonist and a long‑acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Posology<br />The recommended and maximum dose is two inhalations twice daily (two inhalations in the morning and two inhalations in the evening).<br />If a dose is missed, it should be taken as soon as possible and the next dose should be taken at the usual time. A double dose should not be taken to make up for a forgotten dose.</p><p dir="ltr"><br />Special populations</p><p dir="ltr"><br />Elderly<br />No dose adjustments are required in elderly patients (see section 5.2).</p><p dir="ltr">Renal impairment<br />This medicinal product can be used at the recommended dose in patients with mild to moderate renal impairment. It can also be used at the recommended dose in patients with severe renal impairment or end-stage renal disease requiring dialysis, only if the expected benefit outweighs the potential risk (see<br />sections 4.4 and 5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Hepatic impairment<br />This medicinal product can be used at the recommended dose in patients with mild to moderate hepatic impairment. It can also be used at the recommended dose in patients with severe hepatic impairment, only if the expected benefit outweighs the potential risk (see sections 4.4 and 5.2).</p><p dir="ltr">Paediatric population<br />There is no relevant use of this medicinal product in children and adolescents (under 18 years of age) for the indication of COPD.</p><p dir="ltr"><br />Method of administration<br />For inhalation use.<br />Instructions for use</p><p dir="ltr"><br />To ensure proper administration of the medicinal product, the patient should be shown how to use the inhaler correctly by a physician or other healthcare professional, who should also regularly check the adequacy of the patient&#39;s inhalation technique. The patient should be advised to read the Package Leaflet carefully and follow the instructions for use as given in the leaflet.<br />Note: It is important to instruct the patients to:</p><ul dir="ltr"><li>&nbsp;Not use the inhaler if the drying agent, which is inside the foil pouch, has leaked out of its packet. For best results the inhaler should be at room temperature before use.</li><li>Prime the inhaler by shaking it and actuating into the air four times before first use or two times when the inhaler has not been used for more than seven days, after weekly washing or if it has been dropped.</li><li>&nbsp;Rinse their mouth out with water after inhaling the dose to minimise the risk of oropharyngeal thrush. Do not swallow.</li></ul><p dir="ltr">On actuation of Breztri Aerosphere, a volume of the suspension is expelled from the pressurised container. When the patient inhales through the mouthpiece at the same time as actuating the inhaler, the substance will follow the inspired air into the airways.</p><p dir="ltr"><br />Patients who find it difficult to coordinate actuation with inhalation may use Breztri Aerosphere with a spacer to ensure proper administration of the medicinal product. Breztri Aerosphere can be used with spacer devices including the Aerochamber Plus Flow-Vu (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Not for acute use</u></p><p dir="ltr">This medicinal product is not indicated for the treatment of acute episodes of bronchospasm, i.e. as a rescue therapy.</p><p dir="ltr"><u>Paradoxical bronchospasm</u></p><p dir="ltr">Administration of formoterol/glycopyrronium/budesonide may produce paradoxical bronchospasm with an immediate wheezing and shortness of breath after dosing and may be life‑threatening. Treatment with this medicinal product should be discontinued immediately if paradoxical bronchospasm occurs. The patient should be assessed, and alternative therapy instituted if necessary.</p><p dir="ltr"><u>Deterioration of disease</u></p><p dir="ltr">It is recommended that treatment with this medicinal product should not be stopped abruptly. If patients find the treatment ineffective, they should continue treatment, but medical attention must be sought. Increasing use of reliever bronchodilators indicates a worsening of the underlying condition and warrants a reassessment of the therapy. Sudden and progressive deterioration in the symptoms of COPD is potentially life‑threatening and the patient should undergo urgent medical assessment.</p><p dir="ltr"><u>Cardiovascular effects </u></p><p dir="ltr">Cardiovascular effects, such as cardiac arrhythmias, e.g. atrial fibrillation and tachycardia, may be seen after the administration of muscarinic receptor antagonists and sympathomimetics, including glycopyrronium and formoterol. This medicinal product should be used with caution in patients with clinically significant uncontrolled and severe cardiovascular disease such as unstable ischemic heart disease, acute myocardial infarction, cardiomyopathy, cardiac arrhythmias, and severe heart failure.</p><p dir="ltr">Caution should also be exercised when treating patients with known or suspected prolongation of the QTc interval (QTc &gt; 450 milliseconds for males, or &gt; 470 milliseconds for females), either congenital or induced by medicinal products.</p><p dir="ltr"><u>Systemic corticosteroid effects </u></p><p dir="ltr">Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. These effects are much less likely to occur with inhalation treatment than with oral corticosteroids. Possible systemic effects include Cushing&#39;s syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, cataract and glaucoma. Potential effects on bone density should be considered particularly in patients on high doses for prolonged periods that have co‑existing risk factors for osteoporosis.</p><p dir="ltr"><u>Visual disturbances</u></p><p dir="ltr">Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids (see section 4.8).</p><p dir="ltr"><u>Transfer from oral therapy</u></p><p dir="ltr">Particular care is needed in patients transferring from oral steroids, since they may remain at risk of impaired adrenal function for a considerable time. Patients who have required high dose corticosteroid therapy or prolonged treatment at the highest recommended dose of inhaled corticosteroids, may also be at risk. These patients may exhibit signs and symptoms of adrenal insufficiency when exposed to severe stress. Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.</p><p dir="ltr"><u>Pneumonia in patients with COPD </u></p><p dir="ltr">An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been observed in patients with COPD receiving inhaled corticosteroids. There is some evidence of an increased risk of pneumonia with increasing steroid dose but this has not been demonstrated conclusively across all studies.</p><p dir="ltr">There is no conclusive clinical evidence for intra‑class differences in the magnitude of the pneumonia risk among inhaled corticosteroid products.</p><p dir="ltr">Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations. Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index (BMI) and severe COPD.</p><p dir="ltr"><u>Hypokalaemia </u></p><p dir="ltr">Potentially serious hypokalaemia may result from &beta;<sub>2</sub>-agonist therapy. This has the potential to produce adverse cardiovascular effects. Particular caution is advised in severe COPD as this effect may be potentiated by hypoxia. Hypokalaemia may also be potentiated by concomitant treatment with other medicinal products which can induce hypokalaemia, such as xanthine derivatives, steroids and diuretics (see section 4.5).</p><p dir="ltr"><u>Hyperglycaemia </u></p><p dir="ltr">Inhalation of high doses of &beta;<sub>2</sub>-adrenergic agonists may produce increases in plasma glucose. Therefore, blood glucose should be monitored during treatment following established guidelines in patients with diabetes.</p><p dir="ltr"><u>Co-existing conditions</u></p><p dir="ltr">This medicinal product should be used with caution in patients with thyrotoxicosis.</p><p dir="ltr"><u>Anticholinergic activity</u></p><p dir="ltr">Due to its anticholinergic activity, this medicinal product should be used with caution in patients with symptomatic prostatic hyperplasia, urinary retention or with narrow-angle glaucoma. Patients should be informed about the signs and symptoms of acute narrow-angle glaucoma and should be informed to stop using this medicinal product and to contact their doctor immediately should any of these signs or symptoms develop.</p><p dir="ltr">Co-administration of this medicinal product with other anticholinergic containing medicinal products is not recommended (see section 4.5).</p><p dir="ltr"><u>Renal impairment </u></p><p dir="ltr">As glycopyrronium is predominantly renally excreted, patients with severe renal impairment (creatinine clearance of &lt;30&nbsp;mL/min), including those with end-stage renal disease requiring dialysis, should only be treated with this medicinal product if the expected benefit outweighs the potential risk (see section 5.2). &nbsp;</p><p dir="ltr"><u>Hepatic impairment </u></p><p dir="ltr">In patients with severe hepatic impairment, this medicinal product should be used only if the expected benefit outweighs the potential risk (see section 5.2). These patients should be monitored for potential adverse reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pharmacokinetic interactions</u></p><p dir="ltr">Clinical drug-drug interaction studies have not been conducted with this medicinal product, however, the potential for metabolic interactions is considered to be low based on <em>in-vitro</em> studies (see section 5.2).</p><p dir="ltr">Formoterol does not inhibit the CYP450 enzymes at therapeutically relevant concentrations (see section 5.2). Budesonide and glycopyrronium do not inhibit or induce CYP450 enzymes at therapeutically relevant concentrations.</p><p dir="ltr">The metabolism of budesonide is primarily mediated by CYP3A4 (see section 5.2). Co-treatment with strong CYP3A inhibitors, e.g. itraconazole, ketoconazole, HIV protease inhibitors and cobicistat-containing products, are expected to increase the risk of systemic side effects, and should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid adverse reactions, in which case patients should be monitored for systemic corticosteroid adverse reactions. This is of limited clinical importance for short-term (1-2 weeks) treatment.</p><p dir="ltr">Limited data about this interaction for high-dose inhaled budesonide indicates that marked increases in plasma levels (on average four fold) may occur if itraconazole, 200 mg once daily, is administered concomitantly with inhaled budesonide (single dose of 1000 micrograms).</p><p dir="ltr">Since glycopyrronium is eliminated mainly by the renal route, drug interaction could potentially occur with medicinal products affecting renal excretion mechanisms. <em>In vitro,</em> glycopyrronium is a substrate for the renal transporters OCT2 and MATE1/2K. The effect of cimetidine, a probe inhibitor of OCT2 and MATE1, on inhaled glycopyrronium disposition showed a limited increase in its total systemic exposure (AUC<sub>0-t</sub>) by 22% and a slight decrease in renal clearance by 23% due to co-administration of cimetidine.</p><p dir="ltr"><u>Pharmacodynamic interactions</u></p><p dir="ltr"><em>Other antimuscarinics and sympathomimetics</em></p><p dir="ltr">Co-administration of this medicinal product with other anticholinergic and/or long-acting &beta;<sub>2</sub>-adrenergic agonist containing medicinal products has not been studied and is not recommended as it may potentiate known inhaled muscarinic antagonist or &beta;2-adrenergic agonist adverse reactions (see section 4.4 and section 4.9).</p><p dir="ltr">Concomitant use of other beta-adrenergic medicinal products can have potentially additive effects; therefore, caution is required when other beta-adrenergic medicinal products are prescribed concomitantly with formoterol.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Medicinal product-induced hypokalaemia</em></p><p dir="ltr">Possible initial hypokalaemia may be potentiated by concomitant medicinal products, including xanthine derivatives, steroids and non‑potassium sparing diuretics (see section 4.4). Hypokalaemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glycosides.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>&beta;-adrenergic blockers</em></p><p dir="ltr">&beta;-adrenergic blockers (including eye drops) can weaken or inhibit the effect of formoterol. Concurrent use of &beta;-adrenergic blockers should be avoided unless the expected benefit outweighs the potential risk. If &beta;-adrenergic blockers are required, cardio-selective &beta;-adrenergic blockers are preferred.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Other pharmacodynamic interactions</em></p><p dir="ltr">Concomitant treatment with quinidine, disopyramide, procainamide, antihistamines, monoamine oxidase inhibitors, tricyclic antidepressants and phenothiazines can prolong the QT interval and increase the risk of ventricular arrhythmias. In addition, L-dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards beta2-sympathomimetics.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Concomitant treatment with monoamine oxidase inhibitors, including medicinal products with similar properties such as furazolidone and procarbazine, may precipitate hypertensive reactions.</p><p dir="ltr">There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">There are no or limited amount of data from the use of budesonide, glycopyrronium and formoterol in pregnant women.</p><p dir="ltr">Data on the use of inhaled budesonide in more than 2,500 exposed pregnancies indicate no increased teratogenic risk associated with budesonide.&nbsp;Single-dose studies in humans found that very small amounts of glycopyrronium passed the placental barrier.</p><p dir="ltr">There is no experience with or evidence of safety issues on the use of the propellant norflurane (HFA134a) during human pregnancy or lactation. However, studies on the effect of HFA134a on the reproductive function and embryofoetal development in animals revealed no clinically relevant adverse effects.</p><p dir="ltr">No animal reproductive toxicology studies have been conducted with this medicinal product. Budesonide has been shown to induce embryofoetal toxicity in rats and rabbits, a class effect of glucocorticoids.&nbsp;At very high doses/systemic exposure levels, formoterol caused implantation losses as well as decreases in birth weight and early postnatal survival, whereas glycopyrronium had no significant effects on reproduction (see section 5.3).</p><p dir="ltr">Administration of this medicinal product to pregnant women should only be considered if the expected benefit to the mother justifies the potential risk to the foetus.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Breast-feeding</u></p><p dir="ltr">A clinical pharmacology study has shown that inhaled budesonide is excreted in breast milk. However, budesonide was not detected in nursing infant blood samples. Based on pharmacokinetic parameters, the plasma concentration in the child is estimated to be less than 0.17% of the mother&rsquo;s plasma concentration. Consequently, no effects due to budesonide are anticipated in breast-fed children whose mothers are receiving therapeutic doses of this medicinal product.&nbsp;It is not known whether glycopyrronium or formoterol are excreted in human milk. Evidence of transfer of glycopyrronium and formoterol into maternal milk in rats has been reported.</p><p dir="ltr">Administration of this medicinal product to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Fertility</u></p><p dir="ltr">Studies in rats have shown adverse effects on fertility only at dose levels higher than the maximum human exposure to formoterol (see section 5.3). Budesonide and glycopyrronium individually, did not cause any adverse effects on fertility in rats. It is unlikely that this medicinal product administered at the recommended dose will affect fertility in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Breztri Aerosphere has no or negligible influence on the ability to drive and use machines. However, dizziness is an uncommon side effect which should be taken into account when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Summary of the safety profile</u></p><p dir="ltr">The safety profile is characterised by corticosteroid, anticholinergic and &beta;<sub>2</sub>-adrenergic class effects related to the individual components of the combination. The most commonly reported adverse&nbsp;reactions in patients receiving this medicinal product were pneumonia (4.6%), headache (2.7%) and urinary tract infection (2.7%).</p><p dir="ltr"><u>Tabulated list of adverse reactions</u></p><p dir="ltr">The tabulated list of adverse reactions is based on the experience with this medicinal product in clinical trials and experience with the individual components.</p><p dir="ltr">The frequency of adverse reactions is defined using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000) and not known (cannot be estimated from available data).</p><p dir="ltr"><strong>Table 1: Adverse reactions by frequency and system organ class (SOC)</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Preferred term</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Infections and infestations</em></p></td><td style="vertical-align:top"><p>Oral candidiasis</p><p>Pneumonia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><em>Endocrine disorders</em></p></td><td style="vertical-align:top"><p>Signs or symptoms of systemic glucocorticosteroid effects, e.g. hypofunction of the adrenal gland</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top"><p>Anxiety</p><p>Insomnia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p><p>Agitation</p><p>Restlessness</p><p>Nervousness</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Abnormal behaviour</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p><p>Tremor</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Eye disorders</em></p></td><td style="vertical-align:top"><p>Vision blurred (see section 4.4)</p><p>Cataract</p><p>Glaucoma</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Cardiac disorders</em></p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Angina pectoris</p><p>Tachycardia</p><p>Cardiac arrhythmias (atrial fibrillation, supraventricular tachycardia and extrasystoles)<em> </em></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td style="vertical-align:top"><p>Dysphonia</p><p>Cough</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Throat irritation</p><p>Bronchospasm</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top"><p>Bruising</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Urinary retention</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Description of selected adverse reactions</u></p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pneumonia</u></p><p dir="ltr">KRONOS was a 24-week study in a total of 1,896 patients with moderate to very severe COPD (mean post-bronchodilator screening FEV<sub>1</sub> 50% of predicted, standard deviation [SD] 14%), 26% of whom had experienced a COPD exacerbation in the year prior to study entry. The incidence of confirmed pneumonia events reported up to 24 weeks was 1.9% (12 patients) for Breztri Aerosphere (n=639), 1.6% (10 patients) for formoterol fumarate dihydrate/glycopyrronium (FOR/GLY) MDI 5/7.2 micrograms (n=625), 1.9% (6 patients) for formoterol fumarate dihydrate/budesonide (FOR/BUD) MDI 5/160&nbsp;micrograms (n=314) and 1.3% (4 patients) for open-labelled&nbsp;formoterol fumarate dihydrate/budesonide Turbuhaler (FOR/BUD) TBH 6/200 micrograms (n=318). In KRONOS, there were no fatal cases of pneumonia with Breztri Aerosphere. &nbsp;</p><p dir="ltr">ETHOS was a 52-week study in a total of 8,529 patients (in the safety population) with moderate to very severe COPD and a history of moderate or severe exacerbations within the prior 12 months (mean post-bronchodilator screening FEV<sub>1</sub> 43% of predicted, SD 10%). The incidence of confirmed pneumonia was 4.2% (90 patients) for Breztri Aerosphere (n=2144), 3.5% (75 patients) for formoterol fumarate dihydrate/glycopyrronium/budesonide (FOR/GLY/BUD) MDI 5/7.2/80&nbsp;micrograms (n=2124), 2.3% (48 subjects) for FOR/GLY MDI 5/7.2&nbsp;micrograms (n=2125) and 4.5% (96 subjects) FOR/BUD MDI 5/160&nbsp;micrograms (n=2136). In ETHOS, there were five fatal cases of pneumonia during the treatment phase of the study (two with FOR/GLY/BUD MDI 5/7.2/80, three with FOR/GLY MDI and none with Breztri Aerosphere).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Reporting of suspected adverse reactions</u>&nbsp;</p><p dir="ltr">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p dir="ltr">&nbsp;</p><p dir="ltr">To report any side effect(s):</p><ul dir="ltr"><li><strong><em>Saudi Arabia: </em></strong></li></ul><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>- The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp;&nbsp; Toll free phone: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa &nbsp;&nbsp;</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp; Other GCC States:</p><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">An overdose may lead to exaggerated anticholinergic and/or &beta;<sub>2</sub>-adrenergic signs and symptoms; the most frequent of which include blurred vision, dry mouth, nausea, muscle spasm, tremor, headache, palpitations and systolic hypertension. When used chronically in excessive doses, systemic glucocorticosteroid effects may appear.</p><p dir="ltr">There is no specific treatment for an overdose with this medicinal product. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Drugs for obstructive airway diseases, adrenergics in combination with anticholinergics including triple combinations with corticosteroids, ATC code: R03AL11</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr">Breztri Aerosphere contains budesonide, a glucocorticosteroid, and two bronchodilators: glycopyrronium, a long-acting muscarinic antagonist (anticholinergic) and formoterol, a long-acting &beta;<sub>2</sub>-adrenergic agonist.</p><p dir="ltr">Budesonide is a glucocorticosteroid which when inhaled has a rapid (within hours) and dose dependent anti-inflammatory action in the airways.&nbsp;</p><p dir="ltr">Glycopyrronium is a long-acting, muscarinic antagonist, which is often referred to as an anticholinergic. The major targets for anticholinergic drugs are muscarinic receptors located in the respiratory tract. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. Antagonism is competitive and reversible. Prevention of methylcholine and acetylcholine-induced bronchoconstrictive effects was dose-dependent and lasted more than 12 hours.</p><p dir="ltr">Formoterol is a selective &beta;<sub>2</sub>-adrenergic agonist that when inhaled results in rapid and long-acting relaxation of bronchial smooth muscle in patients with reversible airways obstruction. The bronchodilating effect is dose dependent, with an onset of effect within 1-3 minutes after inhalation. The duration of effect is at least 12 hours after a single dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Clinical efficacy</u></em></p><p dir="ltr">The efficacy and safety of Breztri Aerosphere was evaluated in patients with moderate to very severe COPD in two randomised, parallel-group trials, ETHOS and KRONOS. Both studies were multicentre, double-blind studies. Patients were symptomatic with a COPD Assessment Test (CAT) score &ge;10 while receiving two or more daily maintenance therapies for at least 6 weeks prior to screening.</p><p dir="ltr">ETHOS was a 52-week trial (N=8,588 randomised; 60% male, mean age of 65) that compared two inhalations twice daily of Breztri Aerosphere, formoterol fumarate dihydrate/glycopyrronium (FOR/GLY) MDI 5/7.2 micrograms, and formoterol fumarate dihydrate/budesonide (FOR/BUD) MDI 5/160&nbsp;micrograms. Patients had moderate to very severe COPD (post-bronchodilator FEV1 &ge;25% to &lt;65% predicted) and were required to have a history of one or more moderate or severe COPD exacerbations in the year prior to screening. The proportion of patients with moderate, severe and very severe COPD was 29%, 61% and 11% respectively. The mean baseline FEV<sub>1</sub> across all groups was 1,021-1,066&nbsp;mL, and during screening the mean post-bronchodilator percent predicted FEV1 was 43% and mean CAT score was 19.6. The primary endpoint of the ETHOS trial was the rate of on-treatment moderate or severe COPD exacerbations for Breztri Aerosphere compared with FOR/GLY MDI and FOR/BUD MDI.</p><p dir="ltr">KRONOS was a 24-week trial (N=1,902 randomised; 71% male, mean age of 65) that compared two inhalations twice daily of Breztri Aerosphere, FOR/GLY MDI 5/7.2 micrograms, FOR/BUD MDI 5/160&nbsp;micrograms and open-label active comparator formoterol fumarate dihydrate/budesonide Turbuhaler (FOR/BUD TBH) 6/200&nbsp;micrograms. Patients had moderate to very severe COPD (post-bronchodilator FEV1 &ge;25% to &lt;80% predicted). The proportion of patients with moderate, severe and very severe COPD was 49%, 43% and 8% respectively. The mean baseline FEV<sub>1</sub> across all groups was 1,050-1,193&nbsp;mL, and during screening the mean post-bronchodilator percent predicted FEV1 was 50%, over 26% of patients reported a history of one or more moderate or severe COPD exacerbation in the past year and the mean CAT score was 18.3. There was a 28-week extension, for up to 52 weeks of treatment, in a subset of subjects. The primary endpoints of the KRONOS trial were the on-treatment FEV1 area under the curve from 0-4 hours (FEV1 AUC0-4) over 24 weeks for Breztri Aerosphere compared to FOR/BUD MDI and the on-treatment change from baseline in morning pre-dose trough FEV1 over 24 weeks for Breztri Aerosphere compared to FOR/GLY MDI.</p><p dir="ltr">At study entry, the most common COPD medications reported in the ETHOS and KRONOS studies were ICS+LABA+LAMA (39%, 27% respectively), ICS+LABA (31%, 38% respectively) and LAMA+LABA (14%, 20% respectively).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Effect on exacerbations</u></em></p><p dir="ltr"><em>&nbsp;Moderate or severe exacerbations: </em></p><p dir="ltr">In the 52-week ETHOS study, Breztri Aerosphere significantly reduced the annual rate of on-treatment moderate/severe exacerbations by 24% (95%&nbsp;CI: 17, 31; p&lt;0.0001) compared with FOR/GLY MDI (rate; 1.08 vs 1.42 events per patient year) and by 13% (95%&nbsp;CI: 5, 21; p=0.0027) compared with FOR/BUD MDI (rate; 1.08 vs 1.24 events per patient year).</p><p dir="ltr">The benefits observed on annualised rate of moderate/severe COPD exacerbations over 24 weeks in KRONOS were generally consistent with those observed in ETHOS. Improvements compared with FOR/GLY MDI were statistically significant; however improvements compared with FOR/BUD MDI and FOR/BUD TBH did not reach statistical significance.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Severe exacerbations (resulting in hospitalisation or death): </em></p><p dir="ltr">In ETHOS, Breztri Aerosphere numerically reduced the annual rate of on-treatment severe exacerbations by 16% (95%&nbsp;CI: ‑3, 31; p=0.0944) compared with FOR/GLY MDI (rate; 0.13 vs 0.15 events per patient year) and significantly reduced the annual rate of on-treatment severe exacerbations by 20% (95%&nbsp;CI: 3, 34; p=0.0221) compared with FOR/BUD MDI (rate; 0.13 vs 0.16 events per patient year).</p><p dir="ltr">In both studies, benefits on exacerbations were observed in patients with moderate, severe and very severe COPD.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Effects on lung function</u></em></p><p dir="ltr">In ETHOS and KRONOS, Breztri Aerosphere improved on-treatment lung function (FEV<sub>1</sub>) compared with FOR/GLY MDI and FOR/BUD MDI (see Table 2 for ETHOS and Table 3 for KRONOS). There was a sustained effect over the 24-week treatment period in both studies, and over 52 weeks in ETHOS.</p><p dir="ltr"><strong>Table 2: Lung function analyses &ndash; ETHOS (spirometric sub-study)</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:604px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Breztri </strong><strong>Aerosphere</strong><strong> (N=747)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>FOR/GLY MDI</strong></p><p><strong>(N=779)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>FOR/BUD MDI</strong></p><p><strong>(N=755)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Treatment difference</strong></p><p><strong>95%&nbsp;CI</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Breztri Aerosphere vs. FOR/GLY MDI</strong></p></td><td style="vertical-align:top"><p><strong>Breztri Aerosphere vs. FOR/BUD MDI</strong></p></td></tr><tr><td style="vertical-align:top"><p>Trough FEV<sub>1</sub> (mL) over 24 weeks, LS mean change from baseline (SE)</p></td><td style="vertical-align:top"><p>129 (6.5)</p></td><td style="vertical-align:top"><p>86 (6.6)</p></td><td style="vertical-align:top"><p>53 (6.5)</p></td><td style="vertical-align:top"><p>43&nbsp;mL<br />(25, 60)</p><p>p&lt;0.0001</p></td><td style="vertical-align:top"><p>76&nbsp;mL<br />(58, 94)</p><p>p&lt;0.0001<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>FEV<sub>1</sub> AUC<sub>0-4 </sub>over 24 weeks; LS mean change from baseline (SE)</p></td><td style="vertical-align:top"><p>294 (6.3)</p></td><td style="vertical-align:top"><p>245 (6.3)</p></td><td style="vertical-align:top"><p>194 (6.3)</p></td><td style="vertical-align:top"><p>49&nbsp;mL<br />(31, 66)</p><p>p&lt;0.0001<sup>#</sup></p></td><td style="vertical-align:top"><p>99&nbsp;mL<br />(82, 117)</p><p>p&lt;0.0001</p></td></tr></tbody></table><p dir="ltr"># p-value not adjusted for multiplicity in hierarchical testing plan</p><p dir="ltr">LS = least squares, SE = standard error, CI = confidence intervals, N = number in Intent-to-Treat population</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table 3: Lung function analyses &ndash; KRONOS</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:747px"><tbody><tr><td rowspan="2" style="vertical-align:top; width:133px"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top; width:80px"><p><strong>Breztri Aero-sphere</strong><strong> </strong><strong>(N=639)</strong></p></td><td rowspan="2" style="vertical-align:top; width:90px"><p><strong>FOR/</strong></p><p><strong>GLY </strong><strong>MDI</strong></p><p><strong>(N=625)</strong></p></td><td rowspan="2" style="vertical-align:top; width:83px"><p><strong>FOR/</strong></p><p><strong>BUD MDI</strong></p><p><strong>(N=314)</strong></p></td><td rowspan="2" style="vertical-align:top; width:87px"><p><strong>FOR/</strong></p><p><strong>BUD TBH (N=318)</strong></p></td><td colspan="3" style="vertical-align:top; width:306px"><p><strong>Treatment difference</strong></p><p><strong>95% CI</strong></p></td></tr><tr><td style="vertical-align:top; width:62px"><p><strong>Breztri Aerosphere</strong><strong> vs. FOR/GLY MDI</strong></p></td><td style="vertical-align:top"><p><strong>Breztri Aerosphere</strong><strong> vs. FOR/BUD MDI</strong></p></td><td style="vertical-align:top; width:187px"><p><strong>Breztri Aerosphere</strong><strong> vs. FOR/BUD TBH</strong></p></td></tr><tr><td style="vertical-align:top; width:133px"><p>Trough FEV<sub>1</sub> (mL) over 24 weeks, LS mean change from baseline (SE)</p></td><td style="vertical-align:top; width:80px"><p>147 (6.5)</p></td><td style="vertical-align:top; width:90px"><p>125 (6.6)</p></td><td style="vertical-align:top; width:83px"><p>73 (9.2)</p></td><td style="vertical-align:top; width:87px"><p>88 (9.1)</p></td><td style="vertical-align:top; width:62px"><p>22&nbsp;mL<br />(4, 39) p=0.0139</p></td><td style="vertical-align:top"><p>74&nbsp;mL<br />(52, 95) p&lt;0.0001</p></td><td style="vertical-align:top; width:187px"><p>59&nbsp;mL<br />(38, 80) p&lt;0.0001<sup>#</sup></p></td></tr><tr><td style="vertical-align:top; width:133px"><p>FEV<sub>1</sub> AUC<sub>0-4 </sub>over 24 weeks; LS mean change from baseline (SE)</p></td><td style="vertical-align:top; width:80px"><p>305 (8.4)</p></td><td style="vertical-align:top; width:90px"><p>288 (8.5)</p></td><td style="vertical-align:top; width:83px"><p>201 (11.7)</p></td><td style="vertical-align:top; width:87px"><p>214 (11.5)</p></td><td style="vertical-align:top; width:62px"><p>16&nbsp;mL<br />(‑6, 38) p=0.1448<sup>#</sup></p></td><td style="vertical-align:top"><p>104&nbsp;mL<br />(77, 131) p&lt;0.0001</p></td><td style="vertical-align:top; width:187px"><p>91&nbsp;mL<br />(64, 117) p&lt;0.0001</p></td></tr></tbody></table><p dir="ltr"># p-value not adjusted for multiplicity in hierarchical testing plan</p><p dir="ltr">LS = least squares, SE = standard error, CI = confidence intervals, N = number in Intent-to-Treat population</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Symptom relief </u></em></p><p dir="ltr">In ETHOS, the baseline average dyspnoea scores ranged from 5.8 &ndash; 5.9 across the treatment groups. Breztri Aerosphere significantly improved breathlessness (measured using the Transition Dyspnoea Index (TDI) focal score over 24 weeks) compared with FOR/GLY MDI (0.40 units; 95%&nbsp;CI: 0.24, 0.55; p&lt;0.0001) and compared with FOR/BUD MDI (0.31&nbsp;units; 95%&nbsp;CI: 0.15, 0.46; p&lt;0.0001). Improvements were sustained over 52 weeks. In KRONOS, the baseline average dyspnoea scores ranged from 6.3 &ndash; 6.5 across the treatment groups. Breztri Aerosphere significantly improved breathlessness over 24 weeks compared with FOR/BUD TBH (0.46&nbsp;units; 95%&nbsp;CI: 0.16, 0.77; p=0.0031). Improvements compared with FOR/GLY MDI, and FOR/BUD MDI did not reach statistical significance.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Health-related quality of life </u></em></p><p dir="ltr">In ETHOS, Breztri Aerosphere significantly improved disease-specific health status (as assessed by the St. George&rsquo;s Respiratory Questionnaire [SGRQ] total score) over 24 weeks compared with FOR/GLY MDI (improvement ‑1.62; 95%&nbsp;CI: ‑2.27, ‑0.97; p&lt;0.0001) and compared with FOR/BUD MDI (improvement ‑1.38, 95%&nbsp;CI: ‑2.02, ‑0.73; p&lt;0.0001). Improvements were sustained over 52 weeks. In KRONOS, improvements compared with FOR/GLY MDI, FOR/BUD MDI and FOR/BUD TBH did not reach statistical significance.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Use of rescue medication</u></em></p><p dir="ltr">In ETHOS, Breztri Aerosphere significantly reduced the on-treatment use of rescue medication over 24 weeks compared with FOR/GLY MDI (treatment difference ‑0.51 puffs/day; 95%&nbsp;CI: ‑0.68, ‑0.34; p&lt;0.0001) and FOR/BUD MDI (treatment difference ‑0.37 puffs/day; 95%&nbsp;CI: ‑0.54, ‑0.20; p&lt;0.0001). Reductions were sustained over 52 weeks. In KRONOS, differences compared with FOR/GLY MDI, FOR/BUD MDI and FOR/BUD TBH were not statistically significant.</p><p dir="ltr"><u>Paediatric population </u></p><p dir="ltr">The European Medicines Agency has waived the obligation to submit the results of studies with Breztri Aerosphere in all subsets of the paediatric population, in COPD (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Following inhalation of the formoterol, glycopyrronium and budesonide combination, the pharmacokinetics of each component was similar to those observed when each active substance was administered separately.</p><p dir="ltr"><em>Effect of a spacer</em></p><p dir="ltr">The use of this medicinal product with the Aerochamber Plus Flow-Vu spacer in healthy volunteers increased the total systemic exposure (as measured by AUC0-t) to budesonide and glycopyrronium by 33% and 55%, respectively, while exposure to formoterol was unchanged. In patients with good inhalation technique, systemic exposure was not increased with the use of a spacer.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Absorption</u></p><p dir="ltr"><em>Budesonide</em></p><p dir="ltr">Following inhaled administration of this medicinal product in subjects with COPD, budesonide Cmax occurred within 20 to 40&nbsp;minutes. Steady state is achieved after approximately 1 day of repeated dosing of this medicinal product and the extent of exposure is approximately 1.3 times higher than after the first dose.</p><p dir="ltr"><em>Glycopyrronium</em></p><p dir="ltr">Following inhaled administration of this medicinal product in subjects with COPD, glycopyrronium Cmax occurred at 6&nbsp;minutes. Steady state is achieved after approximately 3 days of repeated dosing of this medicinal product and the extent of exposure is approximately 1.8 times higher than after the first dose.</p><p dir="ltr"><em>Formoterol</em></p><p dir="ltr">Following inhaled administration of this medicinal product in subjects with COPD, formoterol Cmax occurred within 40 to 60&nbsp;minutes. Steady state is achieved after approximately 2 days of repeated dosing with this medicinal product and the extent of exposure is approximately 1.4 times higher than after the first dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Distribution</u></p><p dir="ltr"><em>&nbsp;Budesonide</em></p><p dir="ltr">The estimated budesonide apparent volume of distribution at steady-state is 1200&nbsp;L, via population pharmacokinetic analysis. Plasma protein binding is approximately 90% for budesonide.</p><p dir="ltr"><em>Glycopyrronium</em></p><p dir="ltr">The estimated glycopyrronium apparent volume of distribution at steady-state is 5500&nbsp;L, via population pharmacokinetic analysis. Over the concentration range of 2-500&nbsp;nmol/L, plasma protein binding of glycopyrronium ranged from 43% to 54%.</p><p dir="ltr"><em>&nbsp;Formoterol</em></p><p dir="ltr">The estimated formoterol apparent volume of distribution at steady-state is 2400&nbsp;L, via population pharmacokinetic analysis. Over the concentration range of 10‑500&nbsp;nmol/L, plasma protein binding of formoterol ranged from 46% to 58%.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Biotransformation</u></p><p dir="ltr"><em>&nbsp;Budesonide</em></p><p dir="ltr">Budesonide undergoes an extensive degree (approximately 90%) of biotransformation on first passage through the liver to metabolites of low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6 &beta;-hydroxy-budesonide and 16a-hydroxy-prednisolone, is less than 1% of that of budesonide.</p><p dir="ltr"><em>Glycopyrronium</em></p><p dir="ltr">Based on literature, and an <em>in-vitro</em> human hepatocyte study, metabolism plays a minor role in the overall elimination of glycopyrronium. CYP2D6 was found to be the predominant enzyme involved in the metabolism of glycopyrronium.</p><p dir="ltr"><em>Formoterol</em></p><p dir="ltr">The primary metabolism of formoterol is by direct glucuronidation and by O-demethylation followed by conjugation to inactive metabolites. Secondary metabolic pathways include deformylation and sulfate conjugation. CYP2D6 and CYP2C have been identified as being primarily responsible for O‑demethylation.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Elimination</u></p><p dir="ltr"><em>&nbsp;Budesonide</em></p><p dir="ltr">Budesonide is eliminated via metabolism mainly catalysed by the enzyme CYP3A4. The metabolites of budesonide are excreted in urine as such or in conjugated form. Only negligible amounts of unchanged budesonide have been detected in the urine. The effective terminal elimination half-life of budesonide derived via population pharmacokinetic analysis was 5 hours.</p><p dir="ltr"><em>Glycopyrronium</em></p><p dir="ltr">After IV administration of a 0.2&nbsp;mg dose of radiolabelled glycopyrronium, 85% of the dose was recovered in urine 48 hours post dose and some of radioactivity was also recovered in bile. The effective terminal elimination half-life of glycopyrronium derived via population pharmacokinetic analysis was 15 hours.</p><p dir="ltr"><em>&nbsp;Formoterol</em></p><p dir="ltr">The excretion of formoterol was studied in six healthy subjects following simultaneous administration of radiolabelled formoterol via the oral and IV routes. In that study, 62% of the drug related radioactivity was excreted in the urine while 24% was eliminated in the faeces. The effective terminal elimination half-life of formoterol derived via population pharmacokinetic analysis was 10 hours.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Special populations</u></p><p dir="ltr"><em>&nbsp;</em><em><u>Age, gender, race/ethnicity and weight</u></em></p><p dir="ltr">Dose adjustments are not necessary based on the effect of age, gender or weight on the pharmacokinetic parameters of budesonide, glycopyrronium and formoterol. There were no major differences in total systemic exposure (AUC) for all compounds between healthy Japanese, Chinese and Western subjects. Insufficient pharmacokinetic data is available for other ethnicities or races.</p><p dir="ltr"><em><u>Hepatic impairment</u></em></p><p dir="ltr">No pharmacokinetic studies have been performed with this medicinal product in patients with hepatic impairment. However, because both budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe liver impairment. Glycopyrronium is primarily cleared from the systemic circulation by renal excretion and hepatic impairment would therefore not be expected to affect systemic exposure.</p><p dir="ltr"><strong><em>&nbsp;</em></strong><em><u>Renal impairment</u></em></p><p dir="ltr">Studies evaluating the effect of renal impairment on the pharmacokinetics of budesonide, glycopyrronium and formoterol were not conducted.</p><p dir="ltr">The effect of renal impairment on the exposure to budesonide, glycopyrronium and formoterol for up to 24 weeks was evaluated in a population pharmacokinetic analysis. Estimated glomerular filtration rate (eGFR) varied from 31‑192&nbsp;mL/min representing a range of moderate to no renal impairment. Simulation of the systemic exposure (AUC0-12) in subjects with COPD with moderate renal impairment (eGFR of 45&nbsp;mL/min) indicates an approximate 68% increase for glycopyrronium compared to subjects with COPD with normal renal function (eGFR of &gt;90&nbsp;mL/min). Renal function was found not to affect exposure to budesonide or formoterol. Subjects with COPD with both low body weight and moderate-severe impaired renal function may have an approximate doubling of systemic exposure to glycopyrronium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no specific hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.<em>&nbsp;</em></p><p>No studies have been conducted with the combination of budesonide, glycopyrronium and formoterol in respect of genotoxicity, carcinogenic potential and toxicity to reproduction and development.</p><p>In animal reproduction studies, glucocorticosteroids such as budesonide have been shown to induce malformations (cleft palate, skeletal malformations). However, these animal experimental results are not relevant in humans at the recommended doses (see section 4.6). Budesonide demonstrated no tumourigenic potential in mice. In rats, an increased incidence of hepatocellular tumours was observed, considered to be a class-effect in rats from long-term exposure to corticosteroids.</p><p>Animal reproduction studies with formoterol have shown a slightly reduced fertility in male rats at high systemic exposure and implantation losses, as well as decreased early postnatal survival and birth weight at considerably higher systemic exposures than those reached during clinical use. A slight increase in the incidence of uterine leiomyomas has been observed in rats and mice treated with formoterol; an effect which is considered to be a class-effect in rodents after long-term exposure to high doses of &beta;<sub>2</sub>-adrenoreceptor agonists.</p><p>Animal reproduction studies with glycopyrronium have shown reduced rat and rabbit foetal weights, and low body weight gain of rat offspring before weaning at considerably higher systemic exposure than those reached during clinical use. No evidence of carcinogenicity was seen in rats and mice.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Norflurane</p><p dir="ltr">1,2-distearoyl-sn-glycero-3-phosphocholine<em> </em>&nbsp;</p><p dir="ltr">Calcium chloride</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 Months 
To be used within 3 months of opening the pouch
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Do not store above 30<sup>o</sup>C.</p><p dir="ltr">Do not expose to temperatures higher than 50<sup>o</sup>C. Do not pierce the pressurised container. Store in a dry place.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Breztri Aerosphere is a pressurised metered dose inhaler, comprising a coated aluminium canister, a yellow plastic actuator and white mouthpiece with an attached grey plastic dust cap, and a dose indicator. Each inhaler is individually packaged in a foil laminate pouch containing a desiccant sachet and packed in to a carton.</p><p dir="ltr"><br />Pack size of 1 container of 120 actuations.</p><p dir="ltr">Multipacks of 360 (3 containers of 120) actuations.</p><p dir="ltr">Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Any unused medicinal product or waste material should be disposed of in accordance with local requirements. The pressurised container should not be broken, punctured or burnt, even when apparently empty.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AstraZeneca AB
SE-151 85 Södertälje
Sweden

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>